Clinical Trials Browser

Active not recruiting × Immunotherapy, Adoptive × 1 year × Clear all

Lymphoma, Non-Hodgkin

NCT03277729 2026-01-05

A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

Leukemia, Lymphoid, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT04670068 2025-12-22

Phase I Study of Autologous CAR T-Cells Targeting the B7-H3 Antigen in Recurrent Epithelial Ovarian

Phase 1 Active not recruiting

4 enrolled 8 charts

Gynecologic

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT03233854 2025-11-18

CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies

Phase 1 Active not recruiting

56 enrolled

Lymphoid

Burkitt Lymphoma, Neoplasm, Residual

NCT06464185 2025-11-18

A Prospective Clinical Study of CD3-CD20 Bisspecific Antibody Based Therapy Combined With CD19-CAR T Cells in the Treatment of Relapsed Refractory B-cell Non-Hodgkin Lymphoma

Phase 1/2 Active not recruiting

48 enrolled

Lymphoid

Lymphoma, B-Cell

NCT04007029 2025-09-05

Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia

Phase 1 Active not recruiting

24 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT07094477 2025-07-30

Study of Targeted CD22/CD19 CAR-T Therapy for First-line Consolidation of B-cell Lymphoma

Phase 2 Active not recruiting

50 enrolled

Lymphoid

Lymphoma, Lymphoma, B-Cell

NCT04577326 2025-07-25

Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma

Phase 1 Active not recruiting

14 enrolled

Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT03241940 2025-06-29

Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults w/ Recurrent or Refractory B Cell Malignancies

Phase 1 Active not recruiting

33 enrolled

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03186118 2025-06-17

Pilot Study of T-APCs Following CAR T Cell Immunotherapy for CD19+ Leukemia

Phase 1 Active not recruiting

30 enrolled

LymphoidOther hematologic neoplasm

Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04581473 2025-06-05

Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection

Phase 1/2 Active not recruiting

192 enrolled

Gastrointestinal

Pancreatic Neoplasms, Stomach Neoplasms

Clinical Trials

AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Non Hodgkin Lymphoma

A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

Phase I Study of Autologous CAR T-Cells Targeting the B7-H3 Antigen in Recurrent Epithelial Ovarian

CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies

A Prospective Clinical Study of CD3-CD20 Bisspecific Antibody Based Therapy Combined With CD19-CAR T Cells in the Treatment of Relapsed Refractory B-cell Non-Hodgkin Lymphoma

Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia

Study of Targeted CD22/CD19 CAR-T Therapy for First-line Consolidation of B-cell Lymphoma

Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma

Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults w/ Recurrent or Refractory B Cell Malignancies

Pilot Study of T-APCs Following CAR T Cell Immunotherapy for CD19+ Leukemia

Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection